Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β 2 -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis.
Vincent Yi-Fong SuTing-Lin DingYuh-Lih ChangYueh-Ching ChouHsuen-En HwangChian-Ying ChouChia-Chen HsuPublished in: Expert review of clinical pharmacology (2024)
Our findings provide important evidence on the effectiveness and safety of ICS/LABA FDC compared with LAMA for bronchiectasis. BEC/FOR and BUD/FOR were associated with better outcomes than FLU/SAL.